Open-Label, Randomised Trial Comparing Efficacy of Continuous Subcutaneous Insulin Infusion(CSII) and Multiple Daily Insulin Injections (MDII) in Improving Glycemic Control and Quality of Life in Poorly Regulated Type 1 Diabetic Children.
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 38
- 试验地点
- 2
- 主要终点
- metabolic control
研究概览
简要总结
Comparison between insulin pump treatment and multiple daily insulin injections in 38 children with type 1 diabetes4-16 years old. Outcome metabolic control, quality of life, impact of disease and cost effectiveness.
We hypothesised that insulin pump treatment would give a better metabolic control and quality of life.
详细描述
The current standard of insulin treatment in type 1 diabetes is multiple daily insulin injection therapy (MDII). In the seventies, continuous subcutaneous insulin infusion (CSII) was introduced. CSII has been gaining popularity, perhaps because of technical advances resulting in improved patient comfort. In children five randomised studies(1-5) were completed to compare MDII and CSII. No data were gained about quality of life and impact of disease.
In our trial we focussed on quality of life next to metabolic control.
The trial was an open-labelled,randomised trial. Both efficacy and safety data were collected. The trial started with a 14 weeks run in phase, during all patients started MDII.In the following randomisation phase patients were randomised to continue MDII or to CSII.This phase lasted 14 weeks.In the phase thereafter all patients used CSII for 14 weeks. The trial was concluded by a 14 weeks allocated patient preference phase.
Patients were type 1 diabetic children 4-16 years old with poor metabolic control.hypothesis: better metabolic control in CSII, better quality of life in CSII.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 4 Years 至 16 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Type 1 diabetes,
- •Diagnosed by the presence of IA-2,
- •GAD-65 or islet cell cytoplasmatic auto antibodies,
- •Daily insulin adminstration or 1 year of longer,
- •Random C-peptide <200 pMol,
- •Hba1c>8.0% and/or a history of repeated symptomatic hypoglycaemias,
- •Attending regular school
排除标准
- •Clinical manifest chronic complications,
- •Pregnancy,
- •Co-morbidity,
- •Mental retardation,
- •Psychiatric treatment or symptoms in child or parent,
- •Insufficient Dutch language capabilities and absence of telephone at home
结局指标
主要结局
metabolic control
quality of life
次要结局
- cost effectiveness
- surrogate markers for late complications
- adverse events
- impact of disease